UCB partners with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform
Computational advancements enable earlier and more widespread use of antibody-antigen structural insights across drug discovery process These advancements have the potential to transform antibody discovery methods, broadening therapeutic...
CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China
CBC Group and Mubadala acquire UCB's mature neurology and allergy business in China for US$680 million. New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry. Strategic...